Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation presenting as pericardial effusion
In the evolving field of hematology and oncology, addressing acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) is crucial. A recent study highlighting AML relapse as…
EHA China Spotlight | Professor Jing Pan: Previous-Transplant or New-Match Donor CD5 CAR-T Cells in Pediatric and Adult Relapsed/Refractory T-ALL: First-In-Human, Phase 1 Study
CAR-T cell therapy is rapidly advancing in the field of hematologic malignancies, including significant progress in the treatment of T-cell lymphomas. However, challenges such as relapse, off-target effects, and viral…
EHA Expert Interview | Professor Zhiming Li: Zanubrutinib Combined with CHOP Shows Superior Efficacy in Newly Diagnosed DLBCL Patients, Especially in the GCB Subtype
In the treatment of diffuse large B-cell lymphoma (DLBCL), the R-CHOP regimen has been a cornerstone, but enhancing its efficacy remains a significant challenge in the medical community. At the…
EHA Expert Interview | Professors Huilai Zhang and Shiyong Zhou’s Team: Major Advances in Lymphoma Research
The 29th European Hematology Association (EHA) Annual Meeting was grandly held in Madrid, Spain, from June 13-16, 2024. As the largest international conference in the field of hematology in Europe,…
EHA Expert Interview | Professor Jie Jin: Zhejiang University’s Voice Resonates Internationally with GR1803 for RRMM
The 29th European Hematology Association (EHA) Annual Meeting took place from June 13-16, 2024, in Madrid, Spain. As Europe's largest international event in the field of hematology, the meeting attracts…
EHA 2024: Transforming Insights into Action for Better Patient Outcomes
As we reflect on EHA 2024, the impact of this year’s congress continues to resonate within the hematology community. The groundbreaking research, innovative treatment strategies, and expert discussions presented at…
EHA 2024: Pioneering Advances in Hematology and Innovative Therapies
The recent European Hematology Association (EHA) Congress highlighted crucial advancements in hematology, emphasizing the significance of cutting-edge research and its impact on clinical practices. This year's sessions provided invaluable insights…
EHA 2024: Bridging Research and Practice to Elevate Hematology Care
From clinical trials to real-world applications, the EHA Congress has bridged the gap between research and practice, enhancing the standard of care for hematological patients. #EHA2024 #BridgingTheGap